Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will
report its financial results for the quarter ended June 30, 2009, on
Tuesday, August 4, 2009 at approximately 8:00 am Eastern Time (ET). The
release will be followed by a live conference call, which will begin at
approximately 9:00 am Eastern Time (ET) on Tuesday, August 4, 2009.
Participating in the call from Enzon’s executive management team will be
Jeffrey H. Buchalter, President and Chief Executive Officer, and Craig
Tooman, Executive Vice President, Finance and Chief Financial Officer.
All interested parties may access the call by using the following
information:
|
Domestic Dial-In Number:
|
|
(888) 312-3051
|
|
International Dial-In Number:
|
|
(719) 457-2694
|
|
Access Code:
|
|
Enzon
|
The call will also be available via live audio webcast at the following
site: http://investor.enzon.com/eventdetail.cfm?eventid=71133.
Listeners should go to the website at least fifteen minutes before this
event to download and install any necessary audio software. For those
unable to attend the live audio webcast, a replay will be available
beginning approximately one hour after the event. Additionally, a
telephonic rebroadcast will also be available following the call. The
rebroadcast will begin on Tuesday, August 4, 2009 at approximately 12:00
pm Eastern Time (ET) and end on Tuesday, August 11, 2009 at
approximately 12:00 am Eastern Time (ET). It may be accessed using the
following information:
|
Domestic Dial-In Number:
|
|
(888) 203-1112
|
|
International Dial-In Number:
|
|
(719) 457-0820
|
|
Replay Passcode:
|
|
3410491
|
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to
developing, manufacturing and commercializing important medicines for
patients with cancer and other life-threatening conditions. The Company
has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet®
and Adagen®. Enzon’s drug development programs utilize several
cutting-edge approaches, including its industry-leading PEGylation
technology platform and the Locked Nucleic Acid (LNA) technology.
Enzon’s PEGylation technology was used to develop two of its products,
Oncaspar and Adagen, and has created a royalty revenue stream from
licensing partnerships for other products developed using the
technology. Enzon also engages in contract manufacturing for several
pharmaceutical companies to broaden its revenue base. Further
information about Enzon and this press release can be found on the
Company’s web site at www.enzon.com.
Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP,
Finance and
Chief Financial Officer
